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Abstract
In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C
virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of sofosbu-
vir-based treatment compared to current standard treatment in mono-infected patients with
chronic hepatitis C (CHC) genotypes 1–4 in Switzerland. Cost-effectiveness was modelled
from the perspective of the Swiss health care system using a lifetime Markov model. Incre-
mental cost-effectiveness ratios (ICERs) used an endpoint of cost per quality-adjusted life
year (QALY) gained. Treatment characteristics, quality of life, and transition probabilities
were obtained from published literature. Country-specific model inputs such as patient char-
acteristics, mortality and costs were obtained from Swiss sources. We performed extensive
sensitivity analyses. Costs and effects were discounted at 3% (range: 0–5%) per year.
Sofosbuvir-containing treatment in mixed cohorts of cirrhotic and non-cirrhotic patients with
CHC genotypes 1–4 showed ICERs between CHF 10,337 and CHF 91,570 per QALY
gained. In subgroup analyses, sofosbuvir dominated telaprevir- and boceprevir-containing
treatment in treatment-naïve genotype 1 cirrhotic patients. ICERs of sofosbuvir were above
CHF 100,000 per QALY in treatment-naïve, interferon eligible, non-cirrhotic patients in-
fected with genotypes 2 or 3. In deterministic and probabilistic sensitivity analyses, results
were generally robust. From a Swiss health care system perspective, treatment of mixed co-
horts of cirrhotic and non-cirrhotic patients with CHC genotypes 1–4 with sofosbuvir-con-
taining treatment versus standard treatment would be cost-effective if a threshold of CHF
100,000 per QALY was assumed.
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Introduction
Hepatitis C virus (HCV) is a ribonucleic acid (RNA) virus causing acute and chronic hepatitis
[1]. Worldwide, the HCV prevalence is about 3% [2]. In Europe and the US, HCV infection
through injection drug use has become the major transmission route [3]. Although most pa-
tients infected with HCV are symptomless, chronic hepatitis C (CHC) poses a significant risk
of developing cirrhosis and hepatocellular carcinoma, if left untreated [4]. Thus, CHC is a
cause of major health burden causing substantial morbidity and mortality [5]. In the US, costs
of about 6.5 billion per year are estimated [6] despite the availability of antiviral therapy.
The aim of therapy in chronic hepatitis C is to achieve a sustained virological response
(SVR). SVR is defined as undetectable serum HCV RNA after the end of treatment, signalling
eradication of HCV infection [7]. SVR at 12 weeks has shown high concordance with SVR at
24 weeks [7] and has been accepted by regulators in the US and Europe as an appropriate end-
point indicating treatment success [8]. Response to HCV treatment differs according to HCV
genotype, disease stage, and HCV treatment history [9]. Pegylated interferon alpha and ribavi-
rin have long been considered standard of care [8] with SVR rates of 40–50% in genotypes 1
and 4 [10] and SVR rates up to 80% in patients with genotypes 2 and 3 [11]. Due to significant
side effects and contraindications associated with pegylated interferon alpha and ribavirin ther-
apy, direct-acting antivirals have been developed [9]. Protease inhibitors such as telaprevir and
boceprevir have been licensed since 2011 for HCV genotype 1 and have increased SVR rates,
but major safety and efficacy issues persist [9].
Sofosbuvir, a newly developed uridine nucleotide analogue HCV NS5B polymerase inhibi-
tor, has shown high antiviral activity across genotypes and few severe side-effects in a range of
clinical trials including various patient populations [12–16]. In treatment-naïve genotype 1 pa-
tients, triple therapy with sofosbuvir, pegylated interferon alpha and ribavirin for 12 weeks
reached a SVR of 89% in a phase III trial [13]. SVR was 96% and 83% in a phase II trial enroll-
ing treatment-experienced patients with genotypes 2 and 3 receiving 12 weeks of triple therapy
with sofosbuvir, pegylated interferon alpha and ribavirin [16]. Treatment with sofosbuvir in
combination with pegylated interferon alpha and/or ribavirin recently received approval for re-
imbursement by the Swiss statutory health insurance in patients with CHC and fibrosis stage 3
or 4, or symptomatic patients with extra hepatic manifestations [17].
The aim of this cost-effectiveness analysis was to estimate clinical effectiveness in terms of
quality-adjusted life years (QALYs) gained, the direct medical cost, and the cost-effectiveness
in terms of cost per QALY gained, of sofosbuvir-based treatment strategies compared with the
current standard treatment of mono-infected patients with CHC genotypes 1–4. The article fol-
lows the CHEERS statement for reporting health economic evaluations [18].
Materials and Methods
Patient population and treatment strategies
We evaluated non-HIV-infected patients diagnosed with CHC genotypes 1–4. Patient groups
were further subdivided into treatment-naïve versus treatment-experienced and interferon-eli-
gible patients versus patients unsuitable for interferon (interferon-ineligible patients or patients
unwilling to take interferon). To reflect real-life medical practice, we obtained average Swiss
CHC patient characteristics, such as mean age, mean weight and percentage of cirrhotic pa-
tients by genotype, from the Swiss Hepatitis C Cohort Study (SCCS) [19]. This representative
cohort study collects standardised prospective data on demographics, laboratory markers, HIV
infection status, treatment and treatment results of HCV infected patients in Switzerland aged
18 years and over, and is fairly representative of the overall infected population in terms of age,
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sex distribution and risk factors for HCV acquisition [19]. The following data points were ex-
tracted from the SCCS in May 2014. The percentage of cirrhotic patients was 24% in genotype
1, 21% in genotype 2, 25% in genotype 3 and 22% in genotype 4. Mean age was 54, 53 and 51
years and mean body weight 73.5, 73.6 and 73.7 kilograms for genotype 1, genotypes 2 and 3,
and genotype 4, respectively. The percentage of cirrhotic patients obtained from the SCCS was
used for the base-case analysis.
Pairs of treatment strategies containing sofosbuvir and comparator strategies representing
current standard of care were identified by experienced Swiss clinicians, based on their rele-
vance for Switzerland and taking into account the local prevalence of different genotypes. No
treatment was included as the comparator for CHC patients unsuitable for interferon treat-
ment, in the absence of treatment alternatives. Treatment regimens were implemented in the
model as per their marketing authorisations and according to the European Association for the
Study of the Liver (EASL) guidelines [20].
Health economic model characteristics
We used a Markov state-transition model with a life-long time horizon implemented in MS
Excel; the structure is shown in Fig 1. The model structure of two health economic models de-
veloped by the Southampton Health Technology Assessment Centre [21,22] that were submit-
ted to the UK National Institute for Health and Care Excellence (NICE) served as basis and
was adapted to achieve reconciliation with available data from clinical trials. Specifically, mild
(METAVIR [23] score F0-F1, absent or portal fibrosis) and moderate HCV (METAVIR score
F2 or F3, portal fibrosis with few or several septa) states included in the original models were
combined to a non-cirrhotic state to reflect available data from clinical trials. In the resulting
structure, virtual mixed cohorts of 10,000 patients with no cirrhosis or compensated cirrhosis
Fig 1. Structure of the Markov state transition model. Patients can transition from each health state to
death from any cause.
doi:10.1371/journal.pone.0126984.g001
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entered the model at the beginning of CHC treatment. Possible health states included non-cir-
rhotic with SVR, cirrhosis with SVR, decompensated cirrhosis, hepatocellular carcinoma, liver
transplant, post-liver transplant and death (Fig 1). Disease-specific mortality (excess mortality)
and general mortality were included separately; patients were exposed to age-specific probabili-
ties of death in the general population [24] in each health state. The possibility of recurrences
and relapses were tested in sensitivity analysis (dotted arrow in Fig 1). The disease was assumed
not to progress while patients were on treatment and 12 weeks after the end of treatment. Pa-
tients could not die during treatment. A half-cycle correction was used for costs as well as ef-
fects. Costs (Swiss Francs, CHF 2014) and effects were discounted at 3% (range in sensitivity
analysis: 0–5%) as recommended in current literature [25]. We calculated the cost-effectiveness
of sofosbuvir in terms of cost per quality-adjusted life year (QALY) from the perspective of the
Swiss health care system (indirect costs not included). There is no published or generally ac-
cepted cost-effectiveness threshold for Switzerland but other Swiss cost-effectiveness studies
have used CHF 100,000 per QALY gained to distinguish potentially favourable from unfavour-
able incremental cost-effectiveness ratios (ICERs) [26–28].
Model input parameters and assumptions
Transition probabilities, quality of life weights, treatment efficacy and safety data, resource use
data, and treatment-related adverse event (AE) costs were obtained from published clinical
trial reports, other peer-reviewed literature and treatment guidelines. Patient characteristics,
all-cause mortality, treatment-related costs and health state costs were extracted from Swiss-
specific sources.
Annual transition probabilities between health states were extracted from published litera-
ture as referenced in Table 1. Probabilities of death in the general population were obtained
from the Swiss Federal Statistical Office [24].
Treatment duration, efficacy and safety were obtained from randomised and non-rando-
mised phase II and phase III clinical trials as presented and referenced in Table 2. The percent-
ages of patients and the time point at which these patients have discontinued treatment due to
adverse events (AEs) or other reasons before the end of the planned treatment duration are
provided in Table 2. Incidences of adverse events (AEs) such as anaemia, nausea, vomiting and
rash are provided in S1 Table. Efficacy data were obtained from phase II trials if the corre-
sponding phase III trials had missing data, e.g. did not report SVR rates according to cirrhosis
status, or the treatment strategy did not match, e.g. SVR rates were reported for 12 instead of
24 weeks of treatment. There was one head-to-head trial available in genotypes 2 and 3 patients
which compared a combination of sofosbuvir and ribavirin with a regimen consisting of pegy-
lated interferon alpha and ribavirin [13]. Other efficacy and safety data were obtained from
available randomised trials and single-arm studies with comparable patient characteristics.
Quality of life weights (utilities) for the health states represented in the model, based on the
European quality of life questionnaire (EQ-5D), were obtained from published literature
(Table 1). For patients on treatment with sofosbuvir or a comparator, a utility decrement ob-
tained in a sofosbuvir trial based on the short-form health survey (SF-6D) was applied [13].
When non-cirrhotic or cirrhotic patients reached SVR after treatment, utilities obtained in a
UK randomised controlled trial of interferon and ribavirin based on the EQ-5D [29] were
added to the utility of the corresponding health state (Table 1).
Resource use parameters such as tests and procedures related to CHC diagnosis and treat-
ment were obtained from EASL Clinical Practice Guidelines [8,20] (S2 Table). Swiss clinical ex-
perts checked whether they reflected Swiss clinical practice. Experts were selected to represent
Cost-Effectiveness Analysis of Sofosbuvir
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Table 1. Base-case values for model input parameters and ranges used in the sensitivity analyses.
Item Source Base-case DSA ranges PSA distribution and
parameters
Annual
transition
probabilities
From To GT1 others Lower
-25%
Upper
+25%
GT1 others
Non-cirrhotic 30
years
Compensated
cirrhosis
[30], [31] 0.006 0.009 0.0015 0.0105 Beta, α = 9 β
= 1481
Beta, α = 20 β
= 2209
Non-cirrhotic 40
years
Compensated
cirrhosis
[30], [31] 0.010 0.014 0.0025 0.0175 Beta, α = 11 β
= 1088
Beta, α = 21 β
= 1511
Non-cirrhotic 50
years
Compensated
cirrhosis
[30], [31] 0.016 0.025 0.0048 0.0280 Beta, α = 10 β
= 619
Beta, α = 8 β
= 316
Non-cirrhotic, SVR Recurrence Expert
opinion
Not
assessed
in base-
case
Not
assessed
in base-
case
0–0.01 0–0.01 - -
Non-cirrhotic, SVR Re-infection Expert
opinion
Not
assessed
in base-
case
Not
assessed
in base-
case
0–0.01 0–0.01 - -
Compensated
cirrhosis
Decompensated
cirrhosis
[29] 0.039 0.039 0.0219 0.0608 Beta, α = 15 β
= 360
Beta, α = 15 β
= 360
Compensated
cirrhosis
Hepatocellular
carcinoma
[21,22,29] 0.014 0.014 0.0016 0.0392 Beta, α = 2 β
= 136
Beta, α = 2 β
= 136
Compensated
cirrhosis, SVR
Recurrence Expert
opinion
Not
assessed
in base-
case
Not
assessed
in base-
case
0–0.01 0–0.01 - -
Compensated
cirrhosis, SVR
Re-infection Expert
opinion
Not
assessed
in base-
case
Not
assessed
in base-
case
0–0.01 0–0.01 - -
Decompensated
cirrhosis
Hepatocellular
carcinoma
[21,22,29] 0.014 0.014 0.002 0.039 Beta, α = 2 β
= 136
Beta, α = 2 β
= 136
Decompensated
cirrhosis
Liver transplant [22] 0.030 0.030 0.012 0.056 Beta, α = 7 β
= 211
Beta, α = 7 β
= 211
Decompensated
cirrhosis
Death [21,22,29] 0.130 0.130 0.111 0.150 Beta, α = 147
β = 984
Beta, α = 147
β = 984
Hepatocellular
carcinoma
Liver transplant Expert
opinion
0–0.01 0–0.01 - - - -
Hepatocellular
carcinoma
Death [21,22,29] 0.43 0.43 0.37 0.49 Beta, α = 117
β = 155
Beta, α = 117
β = 155
Liver transplant Death, year 1 [22] 0.21 0.21 0.13 0.31 Beta, α = 16 β
= 61
Beta, α = 16 β
= 61
Post-liver
transplant
Death, year 2 [22] 0.057 0.057 0.037 0.082 Beta, α = 23 β
= 379
Beta, α = 23 β
= 379
Probability of
death for the
general
population in
2003*
Age-group Annual 3-month Source Base-case Lower
-25%
Upper
+25%
PSA PSA
15–24 0.000522 0.000130 SFSO 0.000522 0.0004 0.0007 - -
25–34 0.000660 0.000165 SFSO 0.000660 0.0005 0.0008 - -
35–44 0.001128 0.000282 SFSO 0.001128 0.0008 0.0014 - -
45–54 0.002758 0.000689 SFSO 0.002758 0.0021 0.0034 - -
55–64 0.006848 0.001711 SFSO 0.006848 0.0051 0.0086 - -
65–74 0.017697 0.004145 SFSO 0.017697 0.0133 0.0221 - -
77–84 0.054529 0.013540 SFSO 0.054529 0.0409 0.0682 - -
85+ 0.165443 0.040517 SFSO 0.165443 0.1241 0.2068 - -
(Continued)
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all Swiss regions and university hospitals. In Swiss regions without a university hospital, clinical
experts from hospitals experienced in the treatment of HCV patients were included.
For every resource use parameter, we obtained unit costs, if possible, using published Swiss
sources or adjusting foreign sources to reflect Swiss practice. Drug unit costs for HCV treat-
ment and treatment-related AEs were derived from the list of pharmaceutical specialties of the
Swiss Federal Office of Public Health [40]. AE management costs were obtained by multiplying
incidences of AEs such as anaemia, nausea, vomiting and rash with drug unit costs for their
treatment. Unit costs for monitoring were obtained from Swiss tariff lists [41] or the analyses
list of the Swiss Federal Office of Public Health [42]. If not otherwise indicated, unit costs were
for the year 2014. Health state costs for the year 2012 were collected at the Gastroenterology
and Hepatology clinic, University Hospital of Zurich. They thus represent a single centre expe-
rience. All cost parameters are shown in Table 3.
Table 1. (Continued)
Item Source Base-case DSA ranges PSA distribution and
parameters
Quality of life—
utilities
Health state Source Base-case Lower
-25%
Upper
+25%
PSA PSA
Non-cirrhotic [29] 0.74 0.71 0.77 Beta, α = 707
β = 248
Beta, α = 707
β = 248
Compensated
cirrhosis
[29] 0.55 0.44 0.65 Beta, α = 47 β
= 39
Beta, α = 47 β
= 39
Patients on
treatment with SOF
(utility decrement)
[13] -0.15 -0.20 +0.20 Gamma, α =
63 β = 0.002
Gamma, α =
63 β = 0.002
Patients receiving
comparator (utility
decrement)
[13] -0.15 -0.12 -0.18 Gamma, α = 8
β = 0.02
(PegIFN
+RBV)
Gamma, α = 8
β = 0.02
(PegIFN
+RBV)
Patients receiving
comparator (utility
decrement)
[13] -0.15 -0.12 -0.18 Gamma, α =
204 β =
0.0007
(Telaprevir)
Gamma, α =
204 β =
0.0007
(Telaprevir)
Patients receiving
comparator (utility
decrement)
[13] -0.15 -0.12 -0.18 Gamma, α =
143 β =
0.0009
(Boceprevir)
Gamma,
03B1 = 143 β
= 0.0009
(Boceprevir)
SVR (utility
increment)
[29] +0.05 +0.002 +0.17 Gamma, α =
1.25 β = 0.04
Gamma, α =
1.25 β = 0.04
Non-cirrhotic, SVR 0.74+0.05 0.79 - - - -
Cirrhotic, SVR 0.55+0.05 0.60 - - - -
Decompensated
cirrhosis
[29] 0.45 0.39 0.51 Beta, α = 124
β = 151
Beta, α = 124
β = 151
Hepatocellular
carcinoma
[29] 0.45 0.39 0.51 Beta, α = 124
β = 151
Beta, α = 124
β = 151
Liver transplant [29] 0.45 0.39 0.51 Beta, α = 124
β = 151
Beta, α = 124
β = 151
Post-liver
transplant
[29] 0.67 0.61 0.73 Beta, α = 163
β = 80
Beta, α = 163
β = 80
DSA, deterministic sensitivity analysis; GT, genotype; HCC, hepatocellular carcinoma; PegIFN, pegylated interferon; PSA, probabilistic sensitivity
analysis; RBV, ribavirin; SFSO, Swiss Federal Statistical Ofﬁce; SOF, Sofosbuvir; SVR, sustained virological response
*Obtained by converting mortality rates using the formulae probability = 1-exp(-rate*time)
doi:10.1371/journal.pone.0126984.t001
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Subgroup analyses
In subgroup analyses, the cost-effectiveness of sofosbuvir was calculated separately for non-cir-
rhotic (fibrosis stage 0–3) and cirrhotic patients (fibrosis stage 4) based on the METAVIR clas-
sification [23].
Sensitivity analyses
We performed extensive deterministic (DSA) and probabilistic sensitivity analysis (PSA) to ex-
plore the impact of parameter uncertainty on the cost-effectiveness results. The ranges of varia-
tion for DSA and the distributional assumptions and parameters used for PSA are listed in
Tables 1 and 3. SVR rates were varied by ±25% of the base-case SVR rate.
To gain a better understanding of the impact of AEs on the cost-effectiveness of sofosbuvir-
based strategies versus current standard of care, we performed a scenario analysis including
total cost of AE management. The incidence of severe AEs was obtained from published
Table 2. Genotype-specific parameters including treatment efficacy, duration and safety.
Indication [Source] SOF-based and comparator
strategies
SVR Discontinued# Patients with
adverse events
cirrhotic Non-
cirrhotic
Due to AEs Other reasons Any Serious
GT1 TN IE [13,32,33] SOF + PegIFN2a + RBV for 12 wks 80.8% 91.3% 1.7% at 5.3 wks 0.7% at 4.8 wks 95% 1%
PegIFN2a/2b + RBV for 48 wks 23.6% 43.6% 7.0% at 24 wks 24% at 24 wks 96% 1%
TEL + PegIFN2a + RBV for 24/48 wks 61.9% 75.4% NA 23.3% at 18 wks 100% 21%
BOC + PegIFN2b + RBV for 28/48 wks 55.0% 64.1% NA 26.1% at 24 wks 99% 13%
GT1 TN II [34] SOF + RBV for 24 wks 53.3% 68.3% 1% at 12 wks 0% 89% 0%
NT 0% 0% 0% 0% 69% 0%
GT2 TN IE [13]* SOF + RBV for 12 wks 90.9% 98.3% 0% 0% 86% 3%
PegIFN2a/2b + RBV for 24 wks 61.5% 81.5% 12% at 14.9 wks 6 96% 1%
GT2 TN II [12] SOF + RBV for 12 wks 93.3% 91.8% 1% at 0.9 wks 1% at 1.3 wks 89% 5%
NT 0% 0% 0% 0% 78% 0%
GT3 TN IE
[13,16,35,36]
SOF + RBV for 24 wks 92.3% 93.5% 0.4% at 21.5 wks 1.2% at 21.5 wks 92% 4%
SOF + PegIFN2a + RBV for 12 wks 83.3% 100% 0% 0% NA 1%
PegIFN2a/2b + RBV for 24 wks 29.7% 71.2% 10.2% at 10.8
wks
13.6% at 11.9
wks
96% 1%
GT3 TN II [35] SOF + RBV for 24 wks 92.3% 93.5% 0.4% at 21.5 wks 1.2% at 21.5 wks 92% 4%
NT 0% 0% 0% 0% 71% 0%
GT3 TE IE
[16,35,37,38]
SOF + RBV for 24 wks 62% 87% 0.4% at 21.5 wks 1.2% at 21.5 wks 92% 4%
SOF + PegIFN2a + RBV for 12 wks 83.3% 83.3% 8% at 1 wk 0% 96% 1%
PegIFN2a/2b + RBV for 48 wks 35% 35% 36.8% at 24 wks 0% 100% 1%
GT3 TE II [35] SOF + RBV for 24 wks 60% 85% 0.4% at 21.5 wks 1.2% at 21.5 wks 92% 4%
NT 0% 0% 0% 0% 71% 0%
GT4 TN [13,39] SOF + PegIFN2a + RBV for 12 wks 50% 100% 0% 0% 95% 2%
PegIFN2a/2b + RBV for 48 wks 38.6% 50% 14% at 24 wks 26% at 24 wks 96% 1%
BOC, boceprevir; GT, genotype; IE, interferon eligible; II, interferon ineligible; NA, not available; PegIFN, pegylated interferon; RBV, ribavirin; SOF,
sofosbuvir; SVR, sustained virological response; TE, treatment-experienced; TEL, telaprevir; TN, treatment-naïve
* head-to-head comparison trial
# the percentages of patients and the time point at which these patients have discontinued treatment due to adverse events or other reasons before the
end of the planned treatment duration
doi:10.1371/journal.pone.0126984.t002
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clinical trials (Table 2). Costs of AE management were obtained from Bichoupan et al. [43].
The authors reported the total treatment costs for AE management in CHC patients treated
with a combination of telaprevir, pegylated interferon alpha and ribavirin in the USA. We as-
sumed that 80% of these total treatment costs were due to severe AEs. This cost parameter was
adjusted for differences in the amount of services used, approximated by health care expendi-
ture per head of the population [46]. Foreign prices were additionally adjusted using purchas-
ing power parities [45]; prices were further adjusted to the increase in health expenditure using
national statistical data [44].
Results
Base-case analysis
In the base-case analysis including a mixed population of about 25% cirrhotic and 75% non-
cirrhotic CHC patients as seen in the SCCS, the incremental cost-effectiveness of therapy with
sofosbuvir depended on genotype, treatment history, and interferon tolerability (Table 4).
Sofosbuvir-containing treatment regimens in patients with CHC genotype 1–4 led to base-case
ICERs between CHF 10,337 and CHF 91,570 per QALY gained. ICERs are below CHF 50,000
per QALY in treatment-naïve interferon eligible genotype 1 patients and in treatment-naïve in-
terferon ineligible genotype 2 and 3 patients.
ICERs for treatment-naïve genotype 1 and 4 patients receiving sofosbuvir, pegylated inter-
feron alpha and ribavirin for 12 weeks ranged from CHF 10,337 to CHF 36,108 per QALY. The
lowest ICERs for genotype 1 were obtained against telaprevir-containing regimens (CHF
10,337 per QALY) and boceprevir-containing regimens (CHF 13,276 per QALY). Underlying
drug cost differences were smaller in these cases than in comparisons of sofosbuvir, pegylated
interferon alpha and ribavirin with pegylated interferon alpha and ribavirin alone (Table 5). In
treatment-naïve, interferon-ineligible genotype 1 patients, the treatment-related and total costs
for a sofosbuvir-based treatment compared to no treatment were higher, as reflected in a higher
ICER (CHF 86,648 per QALY).
In genotype 2, treatment-naïve patients we observed a substantial difference in the ICERs
(Table 4) for interferon-eligible and interferon-ineligible patients (CHF 76,526 vs. CHF 10,471
per QALY). With a sofosbuvir-based treatment, interferon-ineligible patients gained 2.6
Table 3. Cost parameters and their ranges used in the deterministic and probabilistic sensitivity analyses.
Item Source Base-case
(CHF)
Sensitivity analysis
Treatment-related
drug unit costs
Drug Cost/pack or
injection
Cost/unit
(CHF)
PSA distribution and
parameters (DSA
ranges)
PSA distribution and
parameters (DSA
ranges)
Sofosbuvir, 28x400mg 19208.50 FOPH 1.72 Uniform, α = 14406 β =
24011
Uniform, α = 14406 β =
24011
Ribavirin, 56x400mg 738.25 FOPH 0.03 Uniform, α = 664 β =
812
Uniform, α = 664 β =
812
Peg. Interferon 2a, 180 μg 278.31 FOPH 1.55 Uniform, α = 250 β =
306
Uniform, α = 250 β =
306
Peg. Interferon 2b, 120 μg 314.84 FOPH 2.62 Uniform, α = 283 β =
346
Uniform, α = 283 β =
346
Telaprevir, 42x375mg 2948.70 FOPH 0.019 Uniform, α = 2654 β =
3244
Uniform, α = 2654 β =
3244
Boceprevir, 336x200mg 4163.75 FOPH 0.06 Uniform, α = 3747 β =
4580
Uniform, α = 3747 β =
4580
(Continued)
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Table 3. (Continued)
Item Source Base-case
(CHF)
Sensitivity analysis
Treatment-related
adverse event costs
Item Dosage Source Unit cost Lower -25% Upper +25%
AE costs [43]* 8938.40 6703.80 11173.00
Nausea: 4 wks Metoclopramide 30mg/day FOPH 0.019 - -
Vomiting: 4 wks Metoclopramide 30mg/day FOPH 0.019 - -
Diarrhoea: 4.3 wks Loperamide 2mg/day FOPH 0.241 - -
Pruritus: 4wks Piriton 16mg/day FOPH 0.200 - -
Anaemia: 4 wks Binocrit 40,000/ wk FOPH 0.010 - -
Anaemia: blood transfusion FOPH 3,325.00 - -
Rash: 4 wks Hydrocortisone 1% 15g FOPH 7.90 - -
Thrombocytopenia: 4 wks
Revolade
50mg/day FOPH 1.94 - -
Neutropenia: 2 wks Filgrastim 5 μg/kg/ day FOPH 0.999 - -
Depression: 4 wks Citalopram 20mg/day FOPH 0.064 - -
Treatment-related
monitoring unit
costs
Item Source Unit cost - -
Nurse 1 hour Spitex 79.80 - -
Physician 1 hour Tarmed 181.77 - -
Inpatient care 1 hour Tarmed 23.71 - -
HCV screen (RNA), viral load,
genotype, SVR test, HIV RNA
FOPH 180.00 - -
HBV, Anti-HIV FOPH 20.00 - -
Liver function test FOPH 5.00 - -
Alfa-fetoprotein FOPH 19.30 - -
Alfa-antitrypsin FOPH 23.00 - -
Thyrotrophic, Free T4 FOPH 9.00 - -
Caeruloplasmin FOPH 19.90 - -
Iron FOPH 2.80 - -
Urea and electrolytes FOPH 11.20 - -
Glucose, Alanine
aminotransferase
FOPH 2.50 - -
Pregnancy test FOPH 12.00 - -
Thyroid function tests FOPH 18.00 - -
Full blood count, blood clotting
factors
FOPH 4.20 - -
Ferritin FOPH 7.90 - -
Blood group FOPH 17.10 - -
Autoantibodies FOPH 37.00 - -
Immunoglobulins FOPH 6.20 - -
Ultrasound scan of liver Tarmed 113.69 - -
Chest X-ray Tarmed 75.62 - -
Ultrasound guided biopsy Tarmed 179.05 - -
Ultrasound of liver. Fibroscan Tarmed 77.77 - -
Electrocardiography Tarmed 55.67 - -
Magnetic resonance imaging of
liver
Tarmed 390.14 - -
Pulmonary function test Tarmed 62.15 - -
Liver biopsy Tarmed 255.95 - -
Fibrotest FOPH 69.10 - -
Endoscopy diagnosis Tarmed 337.90 - -
(Continued)
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QALYs compared to no treatment, whereas interferon-eligible patients gained 0.6 QALYs
compared to treatment with pegylated interferon alpha and ribavirin (S3 Table).
In genotype 3, ICERs of interferon-ineligible patients were in the same range for treatment-
naïve (CHF 34,826 per QALY) and treatment-experienced (CHF 45,935 per QALY) patients
(Table 4). The limited difference in ICERs was due to moderately lower QALY gains in treat-
ment-experienced patients (2.1 vs. 2.5 QALY). We also noted a large difference in the cost per
QALY gained of two different sofosbuvir-containing regimens, versus the same comparator,
for the treatment of genotype 3, interferon-eligible patients (S4 Table). A treatment strategy of
sofosbuvir in combination with pegylated interferon alpha and ribavirin for 12 weeks was
clearly more cost effective than a 24 week-alternative without interferon in treatment-experi-
enced (ICERs CHF 16,235 per QALY vs. CHF 74,805 per QALY, respectively) and treatment-
naïve patients (ICERs CHF 38,512 per QALY vs. CHF 91,570 per QALY) (Table 4).
Total and disaggregated costs and QALYs gained per patient are presented in Table 5 for ge-
notype 1. Cost and QALY results for the other HCV genotypes are presented in S3–S5 Tables.
In genotype 1 treatment-naïve patients, drug costs for sofosbuvir-containing regimens were
substantially higher than drug costs for comparator strategies (e.g. CHF 62,862 for sofosbuvir
+pegylated interferon alpha+ribavirin vs. CHF 20,454 for pegylated interferon alpha+-
ribavirin). Monitoring costs were generally lower for sofosbuvir-containing regimens than
Table 3. (Continued)
Item Source Base-case
(CHF)
Sensitivity analysis
Health state costs Item Source Base-case
(CHF)
DSA ranges (CHF) PSA distribution and
parameters
Non-cirrhotic Calc.# 479 64–1301 Gamma, α = 2 β = 224
Non-cirrhotic, mild Expert
opinion§
283 - -
Non-cirrhotic, moderate Expert
opinion§
1138 - -
Non-cirrhotic, SVR Calc.# 366 275–458 Gamma, α = 8 β = 47
Non-cirrhotic, mild, SVR [31]& 348 - -
Non-cirrhotic, moderate, SVR [31]& 426 - -
Compensated cirrhosis Expert
opinion§
2,715 1,357–4,535 Gamma, α = 11 β =
246
Compensated cirrhosis, SVR [31]& 754 282–779 Gamma, α = 5 β = 161
Decompensated cirrhosis Expert
opinion§
20,347 16,561–24,517 Gamma, α = 13 β =
1510
Hepatocellular carcinoma Expert
opinion§
16,944 6,163–33,082 Gamma, α = 6 β =
2865
Liver transplant Expert
opinion§
125,102 93,827–156,378 -
Post-liver transplant Expert
opinion§
19,323 14,492–24,154 Gamma, α = 4 β =
4471
AE, adverse event; Calc., calculation; FOPH, Federal Ofﬁce of Public Health; GP, general practitioner; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV,
human immunodeﬁciency virus; mg, milligram; Peg., pegylated; wks, weeks; RNA, Ribonucleic acid; SOF, Sofosbuvir; SVR, sustained virological
response; TE, treatment-experienced; wks, weeks
* converted from 2012 US Dollars to 2012 Swiss francs by using [44–46]
# weighted average: 77% mild, 23% moderate
§ provided by one of the authors (BM), Gastroenterology and Hepatology clinic, University Hospital of Zurich
& inﬂated by 1.14 to £ 2012 and converted to Swiss Francs (exchange rate 1.52)
doi:10.1371/journal.pone.0126984.t003
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comparator strategies (CHF 3,279 for sofosbuvir+ pegylated interferon alpha+ribavirin vs.
CHF 4,650 for pegylated interferon alpha+ribavirin, respectively), except when the comparator
strategy was no treatment. Health state costs were usually higher in comparator strategies than
sofosbuvir-containing regimens (e.g. CHF 24,403 for pegylated interferon alpha+ribavirin vs.
CHF 8,646 for sofosbuvir+ pegylated interferon alpha+ribavirin). QALYs per patient were al-
ways higher with treatment regimens including sofosbuvir, by 0.4 to 2.6 QALYs.
Subgroup analysis
Subgroup-analyses were performed for cirrhotic and non-cirrhotic patients separately. Gener-
ally, costs per QALY gained were lower in cirrhotic patients than in non-cirrhotic patients
(Table 4). In genotype 1 treatment-naïve, interferon-eligible patients with cirrhosis, sofosbuvir
dominated (was clinically more advantageous and less expensive than) telaprevir- and
Table 4. Summary of base-case, sensitivity and subgroup analysis results.
Indication Treatment and comparator
strategies
Base-case (21–25%
cirrhotic*) ICERs
DSA ranges PSA Subgroup (100%
cirrhotic) ICERs
Subgroup (100%
non-cirrhotic)
ICERs
GT1 TN IE SOF + PegIFN2a + RBV for 12
wks vs. PegIFN2a/2b + RBV for
48 wks
19.474 6,339–31,668 100% of
ICERs<100,000
1,565 36,501
SOF + PegIFN2a + RBV for 12
wks vs. TEL + PegIFN2a + RBV
for 24/48 wks
10,337 SOF
dominant-
44,639
98.2% of
ICERs<100,000
SOF dominant 28,608
SOF + PegIFN2a + RBV for 12
wks vs. BOC + PegIFN2b + RBV
for 28/48 wks
13,276 SOF
dominant-
35,975
100% of
ICERs<100,000
963 26,579
GT1 TN II SOF + RBV for 24 wks vs. NT 86,648 42,713–
148,297
50.8% of
ICERs<100,000
75,799 95,741
GT2 TN IE SOF + RBV for 12 wks vs.
PegIFN2a/2b + RBV for 24 wks
76,526 40,468–
138,263
58.7% of
ICERs<100,000
35,302 115,138
GT2 TN II SOF + RBV for 12 wks vs. NT 10,471 1,080–19,273 100% of
ICERs<100,000
SOF dominant 17,808
GT3 TN IE SOF + RBV for 24 wks vs.
PegIFN2a/2b + RBV for 24 wks
91,570 47,672–
130,036
48.9% of
ICERs<100,000
28,384 189,063
SOF + PegIFN2a + RBV for 12
wks vs. PegIFN2a/2b + RBV for
24 wks
38,512 17,109–
57,694
97.4% of
ICERs<100,000
8,491 74,341
GT3 TN II SOF + RBV for 24 wks vs. NT 34,826 14,649–
53,365
99.5% of
ICERs<100,000
17,275 46,900
GT3 TE IE SOF + RBV for 24 wks vs.
PegIFN2a/2b + RBV for 48 wks
74,805 38,237–
112,762
65.8% of
ICERs<100,000
90,653 76,064
SOF + PegIFN2a + RBV for 12
wks vs. PegIFN2a/2b + RBV for
48 wks
16,235 4,314–26,946 99.7% of
ICERs<100,000
4,382 24,957
GT3 TE II SOF + RBV for 24 wks vs. NT 45,935 20,783–
68,920
96.6% of
ICERs<100,000
36,189 52,720
GT4 TN SOF + PegIFN2a + RBV for 12
wks vs. PegIFN2a/2b + RBV for
48 wks
36,108 17,738–
87,678
83.9% of
ICERs<100,000
89,131 33,054
BOC, boceprevir; DSA, deterministic sensitivity analysis; GT, genotype; ICER, incremental cost-effectiveness ratio; IE, interferon eligible; II, interferon
ineligible; PegIFN, pegylated interferon; PSA, probabilistic sensitivity analysis; RBV, ribavirin; SOF, sofosbuvir; TE, treatment-experienced; TEL, telaprevir;
TN, treatment-naïve; wks, weeks
* percentage of cirrhotic patients depends on genotype: 24% in genotype 1, 21% in genotype 2, 25% in genotype 3 and 22% in genotype 4
doi:10.1371/journal.pone.0126984.t004
Cost-Effectiveness Analysis of Sofosbuvir
PLOS ONE | DOI:10.1371/journal.pone.0126984 May 14, 2015 11 / 20
boceprevir-containing treatment regimens. The cost per QALY was more than CHF 100,000 in
genotypes 2 and 3 treatment-naïve, interferon-eligible, non-cirrhotic patients.
Sensitivity analyses
The majority of the results of the DSA and PSA were robust and remained below CHF 100,000
per QALY gained (Table 4). Discount rates, the utility gain after treatment, and differences in
SVR probabilities (SVR rates were varied by either ±20% of the base-case SVR rate or by esti-
mating 95% confidence intervals assuming a beta distribution) were the most influential pa-
rameters. When we took into account an approximated total cost for severe AE management,
ICERs of sofosbuvir-based treatment versus current standard care generally changed by less
than 5% from the base-case ICERs. In genotype 1, treatment-naïve, interferon-eligible patients,
AE management costs per patient for telaprevir-containing regimens (CHF 1,877) and boce-
previr-containing regimens (CHF 1,162) were higher than AE management costs per patient
for sofosbuvir-based treatment (CHF 89). Hence, the corresponding ICERs of sofosbuvir-
based treatment versus telaprevir-containing regimens (CHF 13,425 per QALY) and bocepre-
vir-containing regimens (CHF 11,633 per QALY) increased by 30% and decreased by 12%
Table 5. Cost (CHF) per patient and cost-effectiveness results in genotype 1.
Indication Parameter Intervention Comparator Δ Comparator Δ Comparator Δ Comparator Δ
GT1 TN IE SOF+PaR 12
wks
PaR 48 wks PbR 48 wks TEL+PaR 48
wks
BOC+PbR 48
wks
Drug costs 62,862 20,454 42,408 20,875 41,987 49,333 13,529 45,135 17,727
AE costs 15 2,064 -2,049 2,064 -2,049 3,086 -3,071 56 -41
Monitoring
costs
3,279 4,650 -1,371 4,650 -1,371 4,115 -836 4,404 -1,125
Total treatment
costs
66,156 27,168 38,988 27,589 38,567 56,534 9,622 49,595 16,561
Health state
costs
8,646 24,403 -15,757 24,398 -15,752 13,986 -5,340 16,897 -8,251
Total cost per
patient
74,802 51,571 23,231 51,987 22,815 70,520 4,282 66,492 8,310
QALYs per
patient*
13.3 12.1 1.2 12.1 1.2 12.9 0.4 12.7 0.6
GT1 TN II SOF+RBV 24
wks
NT Δ
Drug costs 120,184 0 120,184
AE costs 40 0 40
Monitoring
costs
3,502 1,472 2,030
Total treatment
costs
123,726 1,472 122,254
Health state
costs
19,070 35,964 -16,894
Total cost per
patient
142,796 37,436 105,360
QALYs per
patient*
12.6 11.4 1.2
AE, adverse event; BOC, boceprevir; GT, genotype; IE, interferon eligible; II, interferon ineligible; NT, no treatment; PaR, pegylated interferon alpha
+ribavirin; PbR, pegylated interferon beta+ribavirin; QALY, quality-adjusted life year; RBV, ribavirin; SOF, sofosbuvir; TEL, telaprevir; TN, treatment-naïve
* values are rounded to one decimal place
doi:10.1371/journal.pone.0126984.t005
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from base-case, respectively. The ICER for telaprevir-containing regimens increased, because
the incidence of severe AEs was lower than the cumulative incidence of AEs such as anaemia,
nausea, vomiting and rash used in the base-case analysis.
Discussion
Although the initial costs of sofosbuvir-containing regimens were high, AE costs, monitoring
costs and health state costs were generally lower than in active comparator strategies. Addition-
ally, QALYs gained per patient were consistently higher in sofosbuvir-containing regimens. In
the base-case representing a mixed cirrhotic and non-cirrhotic cohort, ICERs for sofosbuvir-
containing treatment regimens were better than CHF 100,000 per QALY, for all comparisons.
In the majority of sensitivity analyses, results were robust. ICERs of sofosbuvir-based regimens
were also lower than CHF 100,000 per QALY in cirrhotic patients, but were above CHF
100,000 per QALY for treatment-naïve, interferon eligible genotype 2 and 3 non-
cirrhotic patients.
SVR, the goal of antiviral therapy, can be achieved with a shorter duration of sofosbuvir-
containing treatment than with other treatment regimens. For patients who are ineligible, in-
tolerant or unwilling to take interferon-based regimens, the combination of sofosbuvir and ri-
bavirin addresses an unmet medical need. There has been a shift in European and American
guidelines in the way that EASL [20] and the American Association for the Study of Liver Dis-
eases (AASLD/IDSA/IAS-USA) [47] no longer recommend treatment with telaprevir or boce-
previr in genotype 1 patients. Given the recent marketing authorisation of a combination pill
of sofosbuvir and ledipasvir for the treatment of HCV genotype 1 patients in October 2014 by
the Food and Drug Administration [48] and more recently by the European Medicines Agency
[49], further guideline adaptations may follow.
In our modelling study, sofosbuvir-containing treatment regimens compared to standard
regimens led to gains in QALYs. This is in contrast to the German Institute for Quality and Ef-
ficiency in Health Care's (IQWiG) conclusion [50] that “there is no data documenting an addi-
tional benefit of sofosbuvir-containing regimens compared to other treatment regimens
because no appropriate analyses were provided by the pharmaceutical company”. IQWiG’s po-
sition was partially due to a lack of head-to-head trials and the use of mixed treatment compar-
isons. Heterogeneity between patient characteristics may limit the validity of mixed treatment
comparisons [51]. As patient characteristics such as age and genotype were comparable be-
tween studies, we regard mixed treatment comparisons as an acceptable approach to integrate
available evidence, in the present case.
Leleu et al. published a cost-effectiveness study of sofosbuvir in mono-infected and co-in-
fected CHC patients in France [52]. The resulting ICERs were better than in our study. Leleu
et al. used a lower utility decrement for patients during treatment with sofosbuvir than for pa-
tients during treatment with comparators [52]. We used the same utility decrement for all
treatments. In the French study, the percentages of cirrhotic patients were up to twice as high
as in the base-case of our study. We showed that ICERs for cirrhotic patients were better than
ICERs for non-cirrhotic patients. Hence, these differences in model input parameters may ex-
plain the variation in the magnitude of the ICERs. Another cost-effectiveness study in France
by Deuffic-Burban et al. [53] compared sofosbuvir-containing treatment regimens and stan-
dard treatments in genotype 1 treatment-naïve CHC patients. The authors concluded that
treatment with sofosbuvir is cost-effective in CHC patients with fibrosis stage 2 or higher [53].
An Italian cost-effectiveness study by Petta et al. [54] compared triple therapies with sofosbu-
vir, boceprevir, and telaprevir. Sofosbuvir-based regimens were cost-effective compared to
boceprevir, except in cirrhotic and IL28B CC patients, and mostly cost-effective compared to
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telaprevir. A third cost-effectiveness study in the US concluded that sofosbuvir-based treat-
ment regimens generally dominated telaprevir or boceprevir-based regimens [55]. The authors
of a Spanish cost-effectiveness study reported that treatment regimens with sofosbuvir, pegy-
lated interferon alpha and ribavirin for 12 weeks were below the considered cost-effectiveness
threshold [56]. Overall, the results of the international cost-effectiveness studies were similar to
the present analysis. However, transferability of cost-effectiveness results between different
countries is limited due to e.g. differences in epidemiology of the disease, clinical practice, con-
sumer preferences and price levels [57].
In Switzerland, there is no formally accepted cost-effectiveness threshold. In 2010, the Swiss
Federal Court of Justice decided that treating a very rare orphan disease at CHF 500,000 per
year was too expensive for the compulsory health insurance to cover, given its small health ben-
efits [58]. The Court further stated that beyond a threshold of CHF 100,000 per QALY, health
insurers cannot be obliged to pay for a treatment [58]. This was the first time that a formal
cost-effectiveness threshold has been suggested for Switzerland to distinguish favourable from
unfavourable ICERs. On this basis, sofosbuvir-containing regimens would be cost-effective
compared to standard treatment. However, this remains arguable and there will be further dis-
cussion, also given widely varying approaches in other countries. NICE's acceptable cost-effec-
tiveness thresholds for the UK are in the range of GBP 20,000 to 30,000 per QALY gained and
are intended to represent the opportunity cost to a fixed National Health Service budget [59].
The cost-effectiveness threshold commonly adopted in studies for the US varies between USD
50,000 to 100,000 per QALY [60]. The World Health Organization (WHO) suggests cost-effec-
tiveness thresholds between 2–3 times the gross domestic product (GDP) per person [61]. The
Swiss GDP per person was CHF 74,010 in 2012 [62]. According to the threshold suggested by
WHO, all results including subgroup analyses would be cost-effective.
An additional point of discussion relates to the fact that thresholds representing the societal
willingness to pay for any intervention leading to health gains may vary depending on the con-
text. This was pointed out in a recent article that emphasized how the cost-effectiveness of
sofosbuvir may dramatically clash with its affordability if the treatment is to be implemented
on a large scale [63]. Not surprisingly, economic studies consider ICERs in distinct subgroups
of patients. This appears palatable in those patients in whom the benefit is clear cut, i.e. patients
with advanced liver fibrosis at high risk of complications, while it becomes increasingly difficult
to accept by payers for patients in whom the life-long risk of complications is relatively small,
i.e. patients with no or minimal fibrosis. Those patients are significantly less likely to die of
HCV-related consequences and treatment-induced viral clearance may lead to less clear
health gains.
Our study has several strengths and limitations relating to the decision-analytic model’s
structural assumptions and available input data. Patient characteristics were obtained from the
SCCS [19]. Swiss patient characteristics are thus reflected and the local applicability of the re-
sults is improved. The validity of the model was assessed by scrutinizing outputs for internal
consistency. Model elements and formulae were thoroughly checked for correctness. We also
compared the structure with that of other models in the field, which supported the
approaches taken.
Clinical input parameters such as transition probabilities and utilities were derived from in-
ternational literature. Transition probabilities reflect the biological course of CHC and mainly
depend on disease characteristics and treatment. European countries with similar treatment
options available should have comparable transition probabilities. The utilities used in our
model were mainly based on UK studies [21,22,29]. Although the EQ-5D is a generic instru-
ment to measure quality of life, the value sets applied to obtain utilities differ between countries
[64]. The values available to us were based on the UK value set. There is no Swiss-specific value
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set, but a recent study reported that the UK value set generates lower utilities than the German
or French value set [65]. Because of the small difference, we have no reason to assume that this
had a substantial impact on our results, at least not in the sense of favouring sofosbuvir. For
sofosbuvir and alternative treatment regimens we used the same utilities according to health
state because treatment-specific utilities were not available. Given the lifelong time horizon of
the model, this should not substantially impact the findings. Treatment characteristics and
medical resource use based on clinical trial data, international literature and European guide-
lines were checked by Swiss clinical experts and generally found to be applicable to the Swiss
situation. A small number of assumptions were, however, modified. For example, all HCV pa-
tients in Switzerland are tested for hepatitis B virus infection while there is no cryoglobulin
test performed.
To the extent feasible, the model was populated with Swiss input parameters for patient
characteristics, health state costs and other unit costs. This implied some uncertainties. For the
patient characteristics implemented in the model, we used data from the SCCS, which reflects
local patient characteristics and medical practice. However, patients in the clinical trials of
sofosbuvir were younger than patients in the SCCS. If relevant SVR effects, adverse event rates,
etc. were age-dependent, this age difference could distort the study results. In addition, we re-
ceived health state costs from one big university hospital in Switzerland, which were based on a
data collection of one year. These costs could differ from those accrued in other settings in
Switzerland, which might lead to different results. Despite these aspects and because the model
structure, underlying assumptions and model parameters were reviewed for appropriateness
by Swiss clinical experts, we believe to have achieved reasonable estimates of the cost effective-
ness of CHC treatment with sofosbuvir in Switzerland.
In the base-case analysis, we only included drug costs for the treatment of AEs due to a lack
of Swiss specific data. In this respect, this modelling study may provide a conservative estimate
of the cost-effectiveness of sofosbuvir-based HCV treatment regimens. In a scenario analysis,
total costs of severe AE management were obtained from a US study [43] and adjusted to Swiss
costs to the extent possible. ICERs in this scenario analysis changed by less than 5% in compar-
ison with the base case, except for telaprevir-containing and boceprevir-containing regimens.
Given differences in regimen-specific AE profiles, data allowing for the inclusion of total AE
management costs (i.e. not only drug costs to treat AEs) might improve ICERs of
sofosbuvir treatment.
Given the model structure and underlying model input parameters (mild and moderate
HCV states (fibrosis stage F0-F3) were combined to a non-cirrhotic state to reflect available
data from clinical trials), it was not possible to calculate ICERs for sofosbuvir-based regimens
compared to standard treatment according to fibrosis stage. Therefore, the model is not able to
reflect the current Swiss treatment limitations. In some cases, SVR rates were obtained from
phase II trials due to missing or inapplicable data from phase III trials. Nevertheless, SVR rates
from phase II and III trials were consistent. The cost-effectiveness for genotype 1 treatment-ex-
perienced could not be assessed due to lack of clinical data. As there are no data available re-
garding the reversibility of complications after treatment and any assumption made would add
uncertainty to the model, we did not consider this and assumed a similar post-treatment clini-
cal course independent from the type of treatment used. Clinical efficacy data were derived
from registration trials and may not fully reflect effectiveness in routine clinical practice due to
compliance and adherence issues, which limits the generalisability of the results. Finally, the
analysis was conducted from the health care system perspective. A broader societal perspective
including indirect costs (e.g. due to loss of productivity, absence from work) would provide ad-
ditional insights into the implications of sofosbuvir-based therapy.
Cost-Effectiveness Analysis of Sofosbuvir
PLOS ONE | DOI:10.1371/journal.pone.0126984 May 14, 2015 15 / 20
Several authors have criticised the high price of sofosbuvir [66–68]. Given a relevant pool of
prevalent, previously untreated HCV cases, budget impact remains an issue among payers and
policy makers, especially due to the high up-front costs. Swiss regulators restricted the reim-
bursement of sofosbuvir-containing treatment to patients with fibrosis stage 3 or 4, or symp-
tomatic patients with extra-hepatic manifestations [17], which reduces initial budget impact.
At the same time, our findings for Switzerland generally indicate acceptable ICERs for sofosbu-
vir-containing regimens, which may initiate further discussion on reimbursement issues. Our
results further provide a benchmark for future treatment regimens in patients with CHC that
are expected to become available in the near future.
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S1 Table. Specific adverse events. BOC, boceprevir; GT, genotype; IE, interferon eligible; II,
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